Resistance of prostate cancer cell lines to COX-2 inhibitor treatment

Matthew Wagner, James Loos, Nicole Weksler, Marin Gantner, Christopher Corless, John Barry, Tomasz (Tom) Beer, Mark Garzotto

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Targeting of cyclooxygenase-2 (COX-2) for cancer chemoprevention is well supported for several tumor types, most notably colon cancer. In contrast, the data for its role in prostate cancer carcinogenesis are correlative only. Thus, we compared the COX-2 expression, activity, and effects of inhibition in prostate cancer cells on COX-2-dependent colon cancer cells. COX-2 levels in benign and malignant human prostate tissue were determined by immunohistochemistry. Compared to colon cancer cells, prostate cancer cells expressed lower levels of COX-2, produced less PGE2, and were resistant to selective COX-2 inhibition. Examination of benign prostatic epithelium from prostatectomy samples demonstrated rare foci of COX-2. Whereas, human prostate cancer sections were uniformly negative for COX-2. In conclusion, these studies indicate the lack of a putative role for COX-2 in prostate cancer development. Direct evidence for the involvement of COX-2 in prostate cancer carcinogenesis is desperately needed.

Original languageEnglish (US)
Pages (from-to)800-807
Number of pages8
JournalBiochemical and Biophysical Research Communications
Volume332
Issue number3
DOIs
StatePublished - Jul 8 2005

Fingerprint

Cyclooxygenase 2 Inhibitors
Cyclooxygenase 2
Prostatic Neoplasms
Cells
Cell Line
Colonic Neoplasms
Therapeutics
Carcinogenesis
Chemoprevention
Prostatectomy
Dinoprostone
Tumors
Prostate
Neoplasms
Epithelium
Immunohistochemistry
Tissue

Keywords

  • Apoptosis
  • Chemoprevention
  • COX-2
  • LNCaP
  • Prostaglandin E2
  • Prostate cancer

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. / Wagner, Matthew; Loos, James; Weksler, Nicole; Gantner, Marin; Corless, Christopher; Barry, John; Beer, Tomasz (Tom); Garzotto, Mark.

In: Biochemical and Biophysical Research Communications, Vol. 332, No. 3, 08.07.2005, p. 800-807.

Research output: Contribution to journalArticle

@article{8c59f4f90da647e6823104bfede9c1e2,
title = "Resistance of prostate cancer cell lines to COX-2 inhibitor treatment",
abstract = "Targeting of cyclooxygenase-2 (COX-2) for cancer chemoprevention is well supported for several tumor types, most notably colon cancer. In contrast, the data for its role in prostate cancer carcinogenesis are correlative only. Thus, we compared the COX-2 expression, activity, and effects of inhibition in prostate cancer cells on COX-2-dependent colon cancer cells. COX-2 levels in benign and malignant human prostate tissue were determined by immunohistochemistry. Compared to colon cancer cells, prostate cancer cells expressed lower levels of COX-2, produced less PGE2, and were resistant to selective COX-2 inhibition. Examination of benign prostatic epithelium from prostatectomy samples demonstrated rare foci of COX-2. Whereas, human prostate cancer sections were uniformly negative for COX-2. In conclusion, these studies indicate the lack of a putative role for COX-2 in prostate cancer development. Direct evidence for the involvement of COX-2 in prostate cancer carcinogenesis is desperately needed.",
keywords = "Apoptosis, Chemoprevention, COX-2, LNCaP, Prostaglandin E2, Prostate cancer",
author = "Matthew Wagner and James Loos and Nicole Weksler and Marin Gantner and Christopher Corless and John Barry and Beer, {Tomasz (Tom)} and Mark Garzotto",
year = "2005",
month = "7",
day = "8",
doi = "10.1016/j.bbrc.2005.05.025",
language = "English (US)",
volume = "332",
pages = "800--807",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Resistance of prostate cancer cell lines to COX-2 inhibitor treatment

AU - Wagner, Matthew

AU - Loos, James

AU - Weksler, Nicole

AU - Gantner, Marin

AU - Corless, Christopher

AU - Barry, John

AU - Beer, Tomasz (Tom)

AU - Garzotto, Mark

PY - 2005/7/8

Y1 - 2005/7/8

N2 - Targeting of cyclooxygenase-2 (COX-2) for cancer chemoprevention is well supported for several tumor types, most notably colon cancer. In contrast, the data for its role in prostate cancer carcinogenesis are correlative only. Thus, we compared the COX-2 expression, activity, and effects of inhibition in prostate cancer cells on COX-2-dependent colon cancer cells. COX-2 levels in benign and malignant human prostate tissue were determined by immunohistochemistry. Compared to colon cancer cells, prostate cancer cells expressed lower levels of COX-2, produced less PGE2, and were resistant to selective COX-2 inhibition. Examination of benign prostatic epithelium from prostatectomy samples demonstrated rare foci of COX-2. Whereas, human prostate cancer sections were uniformly negative for COX-2. In conclusion, these studies indicate the lack of a putative role for COX-2 in prostate cancer development. Direct evidence for the involvement of COX-2 in prostate cancer carcinogenesis is desperately needed.

AB - Targeting of cyclooxygenase-2 (COX-2) for cancer chemoprevention is well supported for several tumor types, most notably colon cancer. In contrast, the data for its role in prostate cancer carcinogenesis are correlative only. Thus, we compared the COX-2 expression, activity, and effects of inhibition in prostate cancer cells on COX-2-dependent colon cancer cells. COX-2 levels in benign and malignant human prostate tissue were determined by immunohistochemistry. Compared to colon cancer cells, prostate cancer cells expressed lower levels of COX-2, produced less PGE2, and were resistant to selective COX-2 inhibition. Examination of benign prostatic epithelium from prostatectomy samples demonstrated rare foci of COX-2. Whereas, human prostate cancer sections were uniformly negative for COX-2. In conclusion, these studies indicate the lack of a putative role for COX-2 in prostate cancer development. Direct evidence for the involvement of COX-2 in prostate cancer carcinogenesis is desperately needed.

KW - Apoptosis

KW - Chemoprevention

KW - COX-2

KW - LNCaP

KW - Prostaglandin E2

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=19744378493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19744378493&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2005.05.025

DO - 10.1016/j.bbrc.2005.05.025

M3 - Article

C2 - 15907789

AN - SCOPUS:19744378493

VL - 332

SP - 800

EP - 807

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -